PRESS RELEASE
16 November 2026 08:30:00 CET

LEADING U.S. PATIENT ADVOCACY GROUPS SUPPORT BROAD ACCESS TO TESTING FOR EARLY DETECTION OF PANCREATIC CANCER

Immunovia AB (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, today announced that multiple leading U.S. cancer patient advocacy groups including the Pancreatic Cancer Action Network (PanCAN), FORCE: Facing Our Risk of Cancer Empowered, the John R. Lewis Legacy Institute, and the National Pancreas Foundation, have expressed support for blood-based tests such as PancreaSure® and called on payers, providers, and policymakers to improve access to testing for early detection of pancreatic cancer in individuals at high risk of the disease.

The letters of support highlight the challenges of high-risk pancreatic cancer surveillance and advocate for affordable access to blood tests like PancreaSure. Immunovia will utilize the letters as the company pursues reimbursement of PancreaSure tests from public and private insurers.

“To fully realize the potential of diagnostic advancements, collaboration across the healthcare ecosystem is critical. We urge payers to work proactively with diagnostics developers, clinicians and the patient community to establish coverage and reimbursement pathways for innovative technologies like PancreaSure,” comments Anna Berkenbilt, MD MMSc, Chief Scientific and Medical Officer, PanCAN.

“We encourage stakeholders, including payers, providers, and policymakers, to consider the unique needs of high-risk individuals when evaluating pancreatic cancer surveillance strategies and coverage decisions. Efforts to reduce barriers, improve access, and support uptake of recommended care can lower costs and improve patient outcomes and quality of life,” says Lisa Schlager, Vice President, Public Policy, FORCE: Facing Our Risk of Cancer Empowered.

“Pancreatic cancer surveillance isn’t reaching everyone equally. The people most likely to benefit are often the ones least likely to have access. A blood-based test like PancreaSure lowers the barrier to entry for high-risk surveillance in a way that in-clinic screening programs often can't,” comments Garry Lowe, Vice Chairperson, John R. Lewis Legacy Institute.

“Pancreatic cancer is often diagnosed at a late stage, when treatment options may be limited. Expanding access to evidence-based surveillance tools for individuals at high risk has the potential to identify disease earlier and provide patients with more opportunities for effective intervention. We support efforts to reduce barriers to surveillance and improve access to innovative technologies that may help improve patient outcomes and quality of life,” said Emily Draud, CFRE, Executive Director of the National Pancreas Foundation.

“These letters of support bolster our request for Medicare coverage and will also be shared with commercial payers as we seek payment for PancreaSure tests with the ultimate goal of surveillance accessibility for all high-risk patients,” says Jeff Borcherding, CEO and President, Immunovia.

For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com

Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit **www.immunovia.com**.